Document:

FORM OF COMMON STOCK CERTIFICATE

 Exhibit 4.1 
  

 
 NUMBER 
OT 
OBALON 
SHARES 
INCORPORATED UNDER THE 
LAWS OF THE STATE 
OF DELAWARE 
CUSIP 67424L 10 0 
SEE REVERSE FOR CERTAIN DEFINITIONS 
This certifies that 
is the record holder of 
FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK $0.001 PAR VALUE
PER SHARE, OF 
Obalon Therapeutics, Inc. 
transferable on the books of the
corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. 
WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers. 
Dated: 
President and 
Chief Executive Officer 
Secretary 
OBALON THERAPEUTICS, INC. 
CORPORATE 
SEAL 
JANUARY 2, 2008 
DELAWARE 
COUNTERSIGNED AND REGISTERED: 
AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC 
(BROOKLYN, NY) TRANSFER AGENT 
AND REGISTRAR 
BY: 
AUTHORIZED SIGNATURE 
HERITAGE BANKNOTE 

 The Corporation shall furnish without charge to each stockholder who so requests a statement of
the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
Such requests shall be made to the Corporation’s Secretary at the principal office of the Corporation. 
 KEEP THIS CERTIFICATE IN A
SAFE PLACE. IF IT IS LOST, STOLEN,OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT CERTIFICATE. 

The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out
in full according to applicable laws or regulations: 

 

					
	TEN COM  	 	–	 	as tenants in common
	TEN ENT	 	–	 	as tenants by the entireties
	JT TEN	 	–	 	as joint tenants with right of survivorship and not as tenants in common
	COM PROP	 	–	 	as community property

											
	UNIF GIFT MIN ACT	 	–	 	 	 	Custodian	 	 
		 		 	(Cust)	 		 	(Minor)
		 		 	under Uniform Gifts to Minors
		 		 	Act	 	 
		 		 		 	(State)    

													
	UNIF TRF MIN ACT  	 	–	 	  
	 	Custodian (until age	 	 	 	)
		 		 	(Cust)	 		 		 	

					
		 	  
	 	under Uniform Transfers
		 	(Minor)	 	

					
		 	to Minors Act	 	  

		 		 	(State)

 
 

  
 Additional abbreviations may
also be used though not in the above list. 
  

							
		 	FOR VALUE RECEIVED, 	 	 	 	hereby sell(s), assign(s) and transfer(s) unto

  

			
	PLEASE INSERT SOCIAL SECURITY OR OTHER	 	
	IDENTIFYING NUMBER OF ASSIGNEE	 	
	     	 	
	 	 	

  

			
	  

	(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
	
	  

	
	  

		
	  
	 	shares

 of the capital stock represented by within Certificate, and do hereby irrevocably constitute and appoint 

 

			
	  
	 	attorney-in-fact

 to transfer the said stock on the books of the within named Corporation with full power of the substitution in the premises.

  

			
	Dated	 	  

  

							
		 	X	 	  

			
		 	X	 	  

	Signature(s) Guaranteed:	 		 	NOTICE:	 	THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER.

  

			
	By	 	 
	THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE
GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15. GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE. SIGNATURE GUARANTEES MUST NOT BE DATED.INVESTORS' RIGHTS AGREEMENT

 Exhibit 4.2 

FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is entered into as of April 29, 2016
by Obalon Therapeutics, Inc., a Delaware corporation (the “Company”), the persons and entities listed on Exhibit A attached hereto (the “Investors”) and the persons and entities listed on Exhibit B
attached hereto (the “Stockholders”). 
 RECITALS 

WHEREAS, certain of the Investors (the “Prior Investors”) are holders of outstanding shares of the Company’s
Series A Preferred Stock (the “Series A Stock”) and/or Series B Preferred Stock (the “Series B Stock”) and/or Series C Preferred Stock (the “Series C Stock”) and/or Series C-1 Preferred
Stock (the “Series C-1 Stock”) and/or Series D Preferred Stock (the “Series D Stock”) and possess registration rights, information rights, rights of first offer and other rights pursuant to a Third Amended and
Restated Investors’ Rights Agreement dated as of August 28, 2014 by and among the Company and such Prior Investors, as amended from time to time thereafter (the “Prior Rights Agreement”). 

WHEREAS, certain Investors (the “Series E Investors”) have agreed to purchase shares of the Company’s Series E
Preferred Stock (the “Series E Stock”) pursuant to a certain Series E Preferred Stock Purchase Agreement by and among the Company and such Series E Investors dated of even date herewith, as amended from time to time
(the “Purchase Agreement”). The Purchase Agreement provides that, as a condition to the Series E Investors’ purchase of Series E Stock thereunder, the Company will enter into this Agreement and the Series E
Investors will be granted the rights set forth herein. 
 WHEREAS, the Company and the Prior Investors desire to enter into this Agreement
in order to amend, restate and replace their rights and obligations under the Prior Rights Agreement with the rights and obligations set forth in this Agreement. Section 4.7 of the Prior Rights Agreement provides that the Prior Rights Agreement
may be amended by the written consent of the holders of 67% of the “Registrable Securities” (as defined in Section 1.1 of the Prior Rights Agreement) and the undersigned parties to this Agreement hold at least 67% of the Registrable
Securities. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the parties agree as follows: 

SECTION 1 
 REGISTRATION
RIGHTS; 
 RESTRICTIONS ON TRANSFERABILITY 

1.1 Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

 “Affiliate” shall mean with respect to any Person, any Person which directly or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person. 

“Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 
 “Conversion Shares” shall mean the Common Stock issued or issuable upon conversion of the Shares. 

“Convertible Securities” shall mean any evidence of indebtedness, shares or other securities convertible into or exchangeable
for Common Stock. 
 “Holder” shall mean any Investor owning or having the right to acquire Registrable Securities or any
assignee thereof in accordance with Section 1.14 hereof; provided, however, that with respect to Section 1.6 hereof and other provisions of this Agreement applicable to a registration pursuant to such section,
“Holder” shall also mean the Stockholders or any assignee thereof. 
 “Initial Public Offering” means the first
sale to the public of shares of Common Stock of the Company pursuant to an effective registration statement filed under the Securities Act. 

“Initiating Holders” shall mean Investors or transferees of the Investors under Section 1.14 hereof who in the
aggregate are Holders of not less than thirty-five percent (35%) of the outstanding Registrable Securities. 
 “Major
Holder” shall mean an Investor or transferees of such Investor who in the aggregate are Holders of not less than five percent (5%) of the fully-diluted shares of the outstanding Registrable Securities on an as-converted to Common Stock
basis. In addition to the foregoing definition, “Major Holder” shall also mean (i) Phagia Technology, Inc. (“Phagia”) or its transferees for so long as Phagia or such transferees hold in the aggregate not less than
five percent (5%) of the fully- diluted shares of the outstanding Registrable Securities on an as-converted to Common Stock basis; (ii) Okapi Ventures, L.P. (“Okapi”) or its transferees for so long as Okapi and its
affiliates or such transferees hold in the aggregate not less than 1,666,667 shares of Preferred Stock (as adjusted for stock splits, stock dividends, reclassification and the like); and (iii) Striker Asia Opportunities Fund Corporation
(“Striker”) for so long as Striker and its affiliates hold in the aggregate not less than 760,000 shares of Preferred Stock (as adjusted for stock splits, stock dividends, reclassification and the like). 

“Options” shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire either Common Stock or
Convertible Securities. 
 “Person” shall mean an individual, a corporation, a partnership, a trust or unincorporated
organization or any other entity or organization. 
 “Preferred Stock” shall mean the Series A Stock, Series B Stock,
Series C Stock, Series C-1 Stock, Series D Stock and Series E Stock of the Company. 

  
 2 

 The terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 

“Registrable Securities” means (a) the Conversion Shares, (b) all shares of Common Stock owned by the Investors,
(c) shares of Common Stock issuable upon conversion of shares of Series C-1 Preferred Stock of the Company issuable upon exercise of that certain Amended and Restated Warrant to Purchase Stock, dated October 1, 2014, issued by the Company
to Square 1 Bank, (d) shares of Common Stock issuable upon conversion of shares of Series D Preferred Stock of the Company issuable upon exercise of that certain Second Warrant to Purchase Stock, dated October 1, 2014, issued by the
Company to Square 1 Bank, (e) shares of Common Stock issuable upon conversion of shares of Series D Preferred Stock of the Company issuable upon exercise of that certain Warrant to Purchase Series D Preferred Stock, dated March 15, 2015,
issued by the Company to AENTIB Group Inc., (f) shares of Common Stock issuable upon conversion of shares of Series D Preferred Stock of the Company issuable upon exercise of that certain Warrant to Purchase Series D Preferred Stock, dated
March 16, 2015, issued by the Company to Beech Hill Securities, Inc. and (g) any Common Stock issued (or issuable upon the conversion or exercise of any warrant, right or other security that is issued) as a dividend or other distribution
with respect to, or in exchange for, or in replacement of, the Common Stock described in clauses (a) or (b) hereof; provided, however, that with respect to Section 1.6 hereof and other provisions of this Agreement applicable to
a registration pursuant to such section, in addition to the foregoing definition, “Registrable Securities” shall also mean all shares of Common Stock owned by Phagia or its transferees. 

“Registration Expenses” shall mean all reasonable expenses incurred by the Company in complying with Sections 1.5, 1.6 and
1.7 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, blue sky fees and expenses, the expense of any special audits incident
to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company) and all reasonable fees and disbursements of one special counsel for all of the Holders who
elect to include their Registrable Securities in any such registration. 
 “Restricted Securities” shall mean the
securities of the Company required to bear the legend set forth in Section 1.3 hereof. 
 “Securities Act”
shall mean the Securities Act of 1933, as amended, or any similar or successor federal statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the
securities registered by the Holders. 
 “Shares” shall mean shares of Series A Stock, Series B Stock, Series C Stock,
Series C-1 Stock, Series D Stock and/or Series E Stock of the Company, as applicable. 

  
 3 

 1.2 Restrictions. The Registrable Securities shall not be sold, assigned, transferred or
pledged except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. The Holder will cause any proposed purchaser, assignee, transferee or pledgee of the
Registrable Securities to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

1.3 Restrictive Legend. Each certificate representing (a) the Shares, (b) the Registrable Securities, and (c) any other
securities issued in respect of the securities referenced in clauses (a) and (b) upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of
Section 1.4 below) be stamped or otherwise imprinted with certain legends, including a legend in substantially the following form (in addition to any legend required under applicable state securities laws): 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.” 
 “THE SHARES REPRESENTED BY
THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AGREEMENTS BETWEEN THE COMPANY AND THE ORIGINAL STOCKHOLDER, COPIES OF WHICH ARE ON FILE WITH THE SECRETARY OF THE COMPANY.” 

Each Holder consents to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted
Securities in order to implement the restrictions on transfer established in this Section 1. 
 1.4 Notice of Proposed
Transfers. The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 1. Prior to any proposed sale, assignment, transfer or pledge
of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transfer, the holder thereof shall give written notice to the Company of such holder’s intention to effect such
transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances of the proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder’s expense by either
(a) an unqualified written opinion of legal counsel who shall, and whose legal opinion shall be, reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transfer of the Restricted Securities may be
effected without registration under the Securities Act, or (b) a “no action” letter from the Commission to the effect that the transfer of such securities without 

  
 4 

 
registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, or (c) any other evidence reasonably satisfactory to counsel to the
Company, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the holder to the Company. The Company will not require such a legal opinion
or “no action” letter (i) in any transaction in which an Investor which is a corporation distributes Restricted Securities solely to its majority owned subsidiaries or affiliates for no consideration, or (ii) in any transaction
in which an Investor which is a partnership distributes Restricted Securities solely to its partners, limited partners, retired partners, members or retired members for no consideration; provided that each transferee agrees in writing to be subject
to the terms of this Section 1. Each certificate evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legends set forth in this
Section 1, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act or this Agreement. 
 1.5 Requested Registration. 

(a) In case the Company shall receive from Initiating Holders a written request that the Company effect any registration, qualification or
compliance with respect to the Registrable Securities, the Company will: 
 (i) promptly give written notice of the proposed registration,
qualification or compliance to all other Holders; and 
 (ii) as soon as practicable and in any event within ninety (90) days after
receipt of such written request, use all reasonable efforts to effect such registration, qualification or compliance (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under
applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are
specified in a written request received by the Company within twenty (20) days after receipt of the written notice from the Company; provided, however, that the Company shall not be obligated to take any action to effect any such registration,
qualification or compliance pursuant to this Section 1.5: 
 (A) In any particular jurisdiction in which the Company would be
required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(B) Prior to six (6) months after the effective date of the Company’s Initial Public Offering; 

  
 5 

 (C) After the Company has effected two (2) such registrations pursuant to this
subparagraph 1.5(a), such registration has been declared or ordered effective and the securities offered pursuant to each such registration have been sold; provided that a majority of Registrable Securities requested for inclusion were in
fact included in such registration; 
 (D) During the period starting with the date sixty (60) days prior to the Company’s good
faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a registration initiated by the Company; provided that the Company is actively employed in good faith in all reasonable
efforts to cause such registration statement to become effective and provided further that the Initiating Holders shall be entitled to include Registrable Securities on such registration pursuant to Section 1.6 hereof; or 

(E) If such registration, qualification or compliance involves securities with an aggregate value less than Ten Million Dollars
($10,000,000). 
 Subject to the foregoing clauses (A) through (E), the Company shall file a registration statement covering the
Registrable Securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders; provided, however, that if (i) in the good faith judgment of the board of directors of the Company
(the “Board”), such, registration would be detrimental to the Company and the Board concludes, as a result, that it is essential to defer the filing of such registration statement at such time, and (ii) the Company shall
furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the Board, it would be detrimental to the Company for such registration statement to be filed in the near future and that it is,
therefore, essential to defer the filing of such registration statement, then the Company shall have the right to defer such filing for up to ninety (90) days after receipt of the request of the Initiating Holders, and provided further, that
the Company shall not defer its obligation in this manner more than once in any twelve (12) month period. 
 (b) Underwriting.
In the event that a registration pursuant to Section 1.5 is for a registered public offering involving an underwriting, the Company shall so advise the Holders as part of the notice given pursuant to Section 1.5(a)(i). The
right of any Holder to registration pursuant to Section 1.5 shall be conditioned upon such Holder’s participation in the underwriting arrangements required by this Section 1.5 and the inclusion of such Holder’s
Registrable Securities in the underwriting, to the extent requested and provided herein. 
 The Company shall (together with all Holders
proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by a majority in interest of the Initiating Holders (which
managing underwriter shall be reasonably acceptable to the Company). Notwithstanding any other provision of this Section 1.5, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a
limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be
allocated among all Holders thereof in proportion, as nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the 

  
 6 

 
registration statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

If any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written
notice to the Company, the managing underwriter and the Initiating Holders. The Registrable Securities or other securities so withdrawn shall also be withdrawn from registration, and such Registrable Securities shall not be transferred in a public
distribution prior to ninety (90) days (one hundred eighty (180) days in the case of the Company’s Initial Public Offering) after the date of the final prospectus used in such public offering. 

1.6 Company Registration. 

(a) Notice of Registration. If at any time or from time to time, the Company shall determine to register any of its securities, either
for its own account or the account of a security holder or holders exercising their respective demand registration rights other than (i) a registration relating solely to employee benefit plans, or (ii) a registration relating solely to a
merger, acquisition or exchange, or (iii) a registration relating to convertible debt transaction, the Company will: 
 (i) promptly
give to each Holder written notice thereof; and 
 (ii) include in such registration (and any related qualification under blue sky laws or
other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests made within twenty (20) days after receipt of such written notice from the Company by any Holder. 

(b) Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an underwriting,
the Company shall so advise the Holders as a part of the written notice given pursuant to Section 1.6(a)(i). In such event, the right of any Holder to registration pursuant to Section 1.6 shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the
Company and the other Holders distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company (or if applicable by the
Holders who have initiated such registration,). Notwithstanding any other provision of this Section 1.6, if the managing underwriter determines in its sole discretion that marketing factors require a limitation of the number of shares to
be underwritten, the managing underwriter may limit the number of Registrable Securities to be included in the registration and underwriting, on a pro rata basis based on the total number of Registrable Securities held by each participating Holder;
but in no event shall the amount of securities of the participating Investors included in the offering be reduced to less than thirty percent (30%) of the total amount of securities included in such registration and offering, unless such
offering is the Initial Public Offering of the Company, in which case the participating Holders may be entirely excluded if the managing 

  
 7 

 
underwriter makes the determination described above and no other stockholder’s securities are included. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder or other holder to the nearest one hundred (100) shares. If any Holder or other holder disapproves of the terms of any such underwriting, such Holder may elect
to withdraw therefrom by written notice to the Company and the managing underwriter. Any securities excluded or withdrawn from such underwriting shall be withdrawn from such registration, and shall not be transferred in a public distribution prior
to ninety (90) days (one hundred eighty (180) days in the case of the Company’s Initial Public Offering) after the date of the final prospectus included in the registration statement relating thereto. 

(c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Section 1.6 prior to the effectiveness of such registration, whether or not any Holder has elected to include securities in such registration. 

1.7 Registration on Form S-3. 

(a) If any Holder or Holders of at least twenty percent (20%) of the then outstanding Registrable Securities requests that the Company
file a registration statement on Form S-3 (or any successor form to Form S-3) for a public offering of shares of Registrable Securities, with a reasonably anticipated aggregate price to the public of at least One Million Dollars ($1,000,000), and
the Company is a registrant entitled to use Form S-3 to register the Registrable Securities for such an offering, the Company shall use all commercially reasonable efforts to cause such Registrable Securities to be registered for the offering on
such form. The Company will (i) promptly give written notice of the proposed registration to all other Holders, and (ii) as soon as practicable, but in no event later than sixty (60) days following the request, use all reasonable
efforts to effect such registration (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with
applicable regulations issued under the Securities Act and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities
as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after such
Holder’s receipt of written notice from the Company. The substantive provisions of Section 1.5(b) shall be applicable to each registration initiated under this Section 1.7. 

(b) Notwithstanding the foregoing, the Company shall not be obligated to take any action pursuant to this Section 1.7: (i) in
any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction
and except as may be required by the Securities Act; (ii) in a given twelve month period, after the Company has effected two (2) such registrations pursuant to subparagraph 1.7(a); or (iii) if the Company shall furnish to such
Holders a certificate signed by the President of the Company stating that, in the good faith judgment of the Board, it would be detrimental to the Company or its stockholders for registration statements to be filed in the near future, then the

  
 8 

 
Company’s obligation to use all commercially reasonable efforts to file a registration statement shall be deferred for up to ninety (90) days provided that the Company shall not defer
its obligation in this manner more than once in any twelve-month period. 
 1.8 Corporate Transaction. In the event of a Corporate
Transaction, the Company shall use reasonable efforts to cause the registration rights described under this Section 1 to be assumed or equivalent registration rights to be substituted by a successor corporation or a parent or subsidiary
of such successor corporation in writing. “Corporate Transaction” means a sale of all or substantially all of the Company’s assets or a merger, consolidation or other capital reorganization or business combination transaction
of the Company with or into another corporation, entity or person or a sale of capital stock such that the stockholders immediately prior to such sale possess less than fifty percent (50%) of the voting power immediately after such sale;
provided however, that (a) the provisions of this Section 1.8 may be waived by the holders of at least sixty-seven percent (67%) of the then outstanding Registrable Securities and (b) the provisions of this
Section 1.8 shall not apply in the event of any Corporate Transaction if all Holders are entitled to receive in exchange for their Registrable Securities consideration consisting solely of (i) cash or (ii) securities of the
acquiring corporation which may be immediately sold to the public without registration under the Securities Act. 
 1.9 Expenses of
Registration. All Registration Expenses, including the reasonable fees and expenses of not more than one special counsel to the Holders, incurred in connection with registrations pursuant to Sections 1.5, 1.6 and 1.7 shall be borne by the
Company. Unless otherwise stated, all Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of the registered securities included in such registration pro rata on the basis of the number of shares
so registered. 
 1.10 Registration Procedures. In the case of each registration, qualification or compliance effected by the Company
pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification and compliance and as to the completion thereof. The Company will, at its expense: 

(a) Prepare and file with the Commission a registration statement with respect to the Registrable Securities and use all commercially
reasonable efforts to cause such registration statement to become and remain effective for at least one hundred twenty (120) days or until the distribution described in the registration statement has been completed; provided, however, that
(i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period that the Holder refrains from selling any securities included in such registration at the request of the Company or an underwriter of
the Common Stock (or any other securities) of the Company and (ii) in the case of any registration on Form S-3 which is intended to be offered on a continuous or delayed basis, such one hundred twenty (120) day period shall be extended, if
necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided
further that applicable rules under the Securities Act governing the obligation to file post-effective amendments permit, in lieu of filing a post-effective amendment which includes (A) any prospectus required by Section 10(a)(3) of the
Securities Act or (B) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation 

  
 9 

 
by reference into the registration statement of information required to be included in (A) and (B) above to be contained in periodic reports filed pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); 
 (b) Furnish to the Holders participating in
such registration and to the underwriters of the securities being registered such reasonable number of copies of the registration statement and amendments and supplements thereto, preliminary prospectus, final prospectus and such other documents as
such underwriters may reasonably request in order to facilitate the public offering of such securities; 
 (c) Cause all such Registrable
Securities registered hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; 

(d) Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(e) As soon as practicable, prepare and file amendments of or supplements to the registration statement or prospectus necessary to comply with
the Securities Act with respect to disposition of the Registrable Securities covered by such registration statement and furnish copies of amendments or supplements to all participating Holders; 

(f) Provide transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP number
for all such Registrable Securities, in each case not later than effective date of such registration; 
 (g) Use all reasonable efforts to
register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions unless the Company is already qualified to do business or subject to service of process
in that jurisdiction; 
 (h) Use all reasonable efforts to furnish, at the request of any Holder requesting registration of Registrable
Securities pursuant to this Section 1.10, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1.10, if such securities are being
sold through underwriters, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering,
addressed to the underwriters and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an
underwritten public offering, addressed to the underwriters; 

  
 10 

 (i) Register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions; 
 (j) Make generally available to its security holders, and to deliver
to each Holder participating in the registration statement, an earnings statement of the Company that will satisfy the provisions of Section 11(a) of the Securities Act covering a period of 12 months beginning after the effective date of such
registration statement as soon as reasonably practicable after the termination of such 12-month period; and 
 (k) In the event of any
underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder and other security holder participating in such
underwriting shall also enter into and perform its obligations under such an agreement. 
 1.11 Indemnification. 

(a) The Company will indemnify each Holder, each of its officers and directors, partners and stockholders and agents of the foregoing, and each
person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 1, and each underwriter, if any, and
each person who controls any underwriter within the meaning of Section 15 of the Securities Act, against all reasonable expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in
settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any
amendment or supplement thereto, incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances in which they were made, not misleading, or any violation by the Company of any rule or regulation promulgated under the Securities Act, the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) or any state securities laws applicable to the Company in connection with any such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers, directors and agents, and each person
controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage,
liability or action, as such expenses are incurred, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or
alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder, controlling person or underwriter and stated to be specifically for use
therein. 

  
 11 

 (b) Each Holder will, if Registrable Securities held by such Holder are included in the
securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter, if any, of the Company’s securities covered by such a registration statement,
each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, and each other such Holder, each of its officers and directors and each person controlling such Holder ● within the meaning
of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such
registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
in which they were made, not misleading, and will reimburse the Company, such Holders, such directors, officers, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or
defending any such claim, loss, damage, liability or action, as such expenses are incurred, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in
such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically for use
therein; provided however that in no event shall any indemnity under this Section 1.11(b) exceed the net proceeds from the offering received by such Holder. 

(c) If the indemnification provided for in this Section 1.11 is held by a court of competent jurisdiction to be unavailable to a
party entitled to indemnification under this Section 1.11 (the “Indemnified Party”) with respect to any loss, liability, claim, damage or expense referred to herein, then the party required to provide indemnification
(the “Indemnifying Party”), in lieu of indemnifying such Indemnified Party hereunder, instead shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in
such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage
or expense, as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of
a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission. 
 (d) Each Indemnified Party shall give notice to the Indemnifying Party promptly after such
Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the
Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such
party’s expense; provided, however, that an Indemnified Party (together with all other Indemnified Parties which may be represented without conflict by one counsel) shall have the right to retain its own separate counsel with the reasonable
fees and expenses to be 

  
 12 

 
paid by the Indemnifying Party if the Indemnified Party reasonably determines that representation of such Indemnified Party would be appropriate due to actual or potential differing interests
between such Indemnified Party and any other party represented by such counsel in such proceeding. The failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this
Section 1 unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the
consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect of such claim or litigation. 
 1.12 Information by Holder. The Holder or Holders of Registrable Securities
included in any registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the distribution proposed by such Holder or Holders as the Company may reasonably request in
writing and as shall be required in connection with any registration, qualification or compliance referred to in this Section 1. 

1.13 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at
any time permit the sale of the Restricted Securities to the public without registration, after such time as a public market exists for the Common Stock of the Company, the Company agrees to use all reasonable efforts to: 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act, at all times
after the effective date that the Company becomes subject to the reporting requirements of the Exchange Act; 
 (b) File with the Commission
in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

(c) So long as an Investor or Stockholder owns any Restricted Securities, to furnish to such Investor or Stockholder forthwith upon request a
written statement by the Company as to its compliance with the reporting requirements of said Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company for an offering of its
securities to the general public) and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports
and documents of the Company and other information in the possession of or reasonably obtainable by the Company as an Investor or Stockholder may reasonably request in availing itself of any rule or regulation of the Commission allowing an Investor
or Stockholder to sell any such securities without registration. 
 1.14 Transfer of Registration Rights. The rights to cause the
Company to register securities granted Investors and Stockholders under Sections 1.5, 1.6 and 1.7, as applicable, may only be assigned to (i) a transferee or assignee who acquires at least thirty percent (30%) of an original
Holder’s Registrable Securities as of the date hereof or (ii) a spouse, sibling, lineal 

  
 13 

 
descendant or ancestor, subsidiary, parent, general partner, limited partner, retired partner, member, retired member, stockholder or Affiliate of a Holder (without restriction as to number of
Shares transferred); provided in each case that prompt written notice of such assignment is given to the Company and such assignee agrees to be bound by the provisions of this Agreement by executing a Joinder Agreement in the form attached hereto as
Exhibit C. 
 1.15 Market Stand-off Agreement. Each Holder agrees in connection with the Initial Public Offering of the
Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan) that, upon request of the underwriters managing any underwritten offering of the Company’s securities, not to sell, make any
short sale of, loan, grant any option for the purchase of, pledge, hypothecate or otherwise directly or indirectly dispose of any Registrable Securities (other than those included in the registration) or other capital stock of the Company or
securities exchangeable or convertible into capital stock of the Company without the prior written consent of such underwriters for such period of time (not to exceed one hundred eighty (180) days from the date of the final prospectus used in
such registration) as may be requested by such managing underwriters, and to enter into a lock-up agreement in customary form with such underwriters consistent with the foregoing, provided that all officers and directors of the Company and holders
of at least one percent (1%) of the Company’s capital stock are bound by and have entered into similar agreements. The certificates for the (a) Shares, (b) Registrable Securities and (c) any other securities issued in
respect of the securities referenced in clauses (a) and upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event shall contain, for so long as such market stand-off provision remains in place, certain
legends, including a legend in substantially the following form: 
 “THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER INCLUDING A MARKET STAND-OFF AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL STOCKHOLDER THAT PROHIBITS SALE OR TRANSFER OF SUCH SHARES FOR A PERIOD OF UP TO 180 DAYS FOLLOWING THE DATE OF
THE FINAL PROSPECTUS FOR THE INITIAL PUBLIC OFFERING OF THE ISSUER’S COMMON STOCK. THIS AGREEMENT IS BINDING UPON TRANSFEREES. A COPY OF THE AGREEMENT IS ON FILE WITH THE SECRETARY OF THE ISSUER.” 

1.16 Termination of Rights. The rights of any particular Holder or permitted transferee thereof to cause the Company to register
securities under Sections 1.5, 1.6 and 1.7 shall terminate with respect to such Holder on the date when such Holder can sell all of its Registrable Securities in a single transaction pursuant to Rule 144 of the Securities Act. 

SECTION 2 
 RIGHT OF
FIRST OFFER 
 2.1 Right of First Offer. Subject to the terms and conditions contained in this Section 2, the Company
hereby grants to each Investor the right of first offer (the “Right of First  

  
 14 

 
Offer”) to purchase up to its Pro Rata Portion (as defined below) of any New Securities (as defined in Section 2.2) which the Company may, from time to time, propose to
sell and issue. An Investor’s “Pro Rata Portion” for purposes of this Section 2 shall be equal to (x) the sum of the number of shares of the Company’s Common Stock then held by such Investor after giving
effect to the conversion of all shares of Preferred Stock then held by such Investor, divided by (y) the sum of the total number of shares of the Company’s Common Stock then outstanding after giving effect to the conversion of all
outstanding shares of Preferred Stock held by all Investors. 
 2.2 Definition of New Securities. Except as set forth below,
“New Securities” shall mean any shares of capital stock of the Company, including Common Stock and Preferred Stock, whether authorized or not, and rights, options or warrants to purchase said shares of Common Stock or Preferred
Stock, and securities of any type whatsoever that are, or may become, convertible into said shares of Common Stock or Preferred Stock. Notwithstanding the foregoing, “New Securities” does not include: 

(a) shares of Common Stock and options, warrants or other rights to purchase Common Stock issued or issuable to employees, officers or
directors of, or consultant or advisors to the Company or any subsidiary pursuant to stock grants, restricted stock purchase agreements, option plans, purchase plans, incentive programs or similar arrangements, in each case only if and to the extent
such grants are approved by the Board of Directors, including the Preferred Directors (as such term is defined in the Company’s Seventh Amended and Restated Certificate of Incorporation, as may be amended from time to time); 

(b) shares of Common Stock issued or issuable upon stock splits, or as a dividend or distribution on, or upon conversion of, the Preferred
Stock; 
 (c) shares of Common Stock issued or issuable for consideration other than cash pursuant to a merger, consolidation, acquisition
or similar business combination, provided that such issuance has been approved by the holders of at least sixty-seven percent (67%) of the then outstanding Preferred Stock; 

(d) shares of Common Stock or Preferred Stock issued or issuable to banks, equipment lessors or other financial institutions pursuant to a
debt financing or commercial leasing transaction approved by the Board of Directors, including the Preferred Directors; 
 (e) shares of
Common Stock issued or issuable in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreement or strategic partnership approved by the Board of Directors, including the Preferred
Directors; and 
 (f) shares of Series C Stock, Series C-1 Stock and/or Series D Stock (and shares of Common Stock issuable upon conversion
of such Series C Stock, Series C-1 Stock and/or Series D Stock) issued upon exercise of any warrants that are outstanding prior to the Initial Closing (as defined in the Purchase Agreement). 

2.3 Notice of Right. In the event the Company proposes to undertake an issuance of New Securities, it shall give each Investor written
notice of its intention, describing the type of 

  
 15 

 
New Securities and the price and terms upon which the Company proposes to issue the same. The Investors shall have twenty (20) days from the date of receipt of any such notice to agree to
purchase shares of such New Securities (up to the Pro Rata Portion computed pursuant to Section 2.1), for the price and upon the terms specified in the notice, by giving written notice to the Company and stating therein the quantity of
New Securities to be purchased. If any Investor does not indicate an interest in purchasing any such Investor’s full Pro Rata Portion of such New Securities by the end of the 20-day period, the Company shall give notice of any remaining
available New Securities (the “Overallotment Notice”) to each of the other Investors who has elected to purchase its full Pro Rata Portion (the “Electing Holders”). Such Overallotment Notice may be made by telephone
if confirmed in writing within two (2) days. The Electing Holders shall then have ten (10) days from the date such Overallotment Notice was given to provide the Company with written notice of their election to purchase some or all of the
New Securities subject to the Overallotment Notice. In the event that the number of additional New Securities the Electing Holders elect to purchase (the “Oversubscribing Holders”) exceeds the number of available New Securities, the
number of additional New Securities shall be apportioned ratably amongst the Oversubscribing Holders based on the number of shares of Preferred Stock and Common Stock (on an as-converted to Common Stock basis) then held by each such Oversubscribing
Holder. 
 2.4 Exercise of Right. If any Investor exercises its Right of First Offer hereunder, the closing of the purchase of the
New Securities with respect to which such right has been exercised shall take place as soon as practicable after the Investor gives notice of such interest. 

2.5 Lapse and Reinstatement of Right. In the event an Investor fails to exercise the Right of First Offer provided in this
Section 2 in the manner provided above, the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within sixty
(60) days from the date of said agreement) to sell the New Securities not elected to be purchased by such Investor at the price and upon the terms no more favorable to the purchasers of such securities than specified in the Company’s
notice. In the event the Company has not sold the New Securities or entered into an agreement to sell the New Securities within said ninety (90) day period (or sold and issued New Securities in accordance with the foregoing within sixty
(60) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities without first offering such securities to the Investor in the manner provided above. 

2.6 Transfer of Right of First Offer. The Right of First Offer granted under Section 2 of this Agreement may be assigned to
a transferee or assignee reasonably acceptable to the Company in connection with any transfer of shares of the Company’s capital stock held by an Investor; provided that (a) such transfer may otherwise be effected in accordance with
applicable securities laws; (b) written notice of such assignment is given to the Company; and (c) the transferee executes a written agreement to be bound by the terms of this Agreement. Notwithstanding the above, an Investor that is a
venture capital fund may assign or transfer such rights to an affiliated venture capital fund so long as the transferee agrees to be bound by the terms of this Agreement by executing a Joinder Agreement in the form attached hereto as Exhibit
C. 

  
 16 

 2.7 Termination of Right of First Offer. The Right of First Offer granted under this
Section 2 of this Agreement shall not apply to, and shall terminate and be of no further force or effect upon the effective date of, the Company’s Initial Public Offering. 

SECTION 3 
 AFFIRMATIVE
COVENANTS OF THE COMPANY 
 The Company hereby covenants and agrees as follows: 

3.1 Financial Information. The Company will furnish to each Major Holder or transferee thereof under Section 1.14 the
following reports: 
 (a) As soon as practicable after the end of each fiscal year, and in any event within one hundred twenty
(120) days thereafter, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year,
prepared in accordance with generally accepted accounting principles applied on a consistent basis and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and audited by independent
public accountants of national standing selected by the Company and approved by the Board; 
 (b) As soon as practicable after the end of
each quarter, and in any event within forty-five (45) days thereafter (other than the last calendar month of each fiscal year), unaudited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of the quarter, and
unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such quarter, prepared in accordance with generally accepted accounting principles applied on a consistent basis and setting forth in each
case in comparative form the figures for the same quarter one year earlier; provided that footnotes and schedule disclosure appearing in audited financial statements shall not be required, all in reasonable detail and signed by the principal
financial or accounting officer of the Company; 
 (c) As soon as practicable after the end of each month, and in any event within thirty
(30) days thereafter (other than the last calendar month of each fiscal year), unaudited consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of the month, and unaudited consolidated statements of income and
cash flows of the Company and its subsidiaries, if any, for such month, prepared in accordance with generally accepted accounting principles applied on a consistent basis and setting forth in each case in comparative form the figures for the same
month one year earlier; provided that footnotes and schedule disclosure appearing in audited financial statements shall not be required, all in reasonable detail and signed by the principal financial or accounting officer of the Company; 

(d) As soon as practicable, but in any event at least thirty (30) days prior to the beginning of each fiscal year, a budget for the next
fiscal year, prepared on a monthly basis, and, as soon as prepared, any other updated or revised budgets for such fiscal year prepared by the Company and approved by the Board. 

  
 17 

 3.2 Inspection. The Company shall permit each Major Holder, at such Major Holder’s
expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers during normal business hours and upon three (3) business
days’ prior written notice from such Major Holder. 
 3.3 Confidentiality. Each Major Holder agrees and will cause any
representative of such Major Holder to hold in confidence and trust and not use or disclose any information provided to or learned by it in connection with its rights under this Section 3 that is identified in writing as confidential
(the “Confidential Information”), except that such Major Holder may disclose such information to any partner, member, stockholder, subsidiary or parent or professional advisor of such Major Holder for the purpose of evaluating its
investment in the Company as long as (x) (a) such partner, member, stockholder, subsidiary or parent or professional advisor is advised of the confidentiality provisions of this Section 3.3 and (b) such Major Holder uses
commercially reasonable efforts to ensure that such partner, member, stockholder, subsidiary or parent or professional advisor holds such information in confidence and trust and will not use or disclose any information provided to or learned by it
except as required by law. Notwithstanding the above, this Section 3.3 shall not apply to any information which any such Major Holder can prove: 

(a) was in the public domain at the time it was disclosed or has entered the public domain through no fault of such Major Holder; 

(b) was known to such Major Holder, without restriction, at the time of disclosure, as demonstrated by files in existence at the time of
disclosure; 
 (c) is disclosed with the prior written approval of the Company; 

(d) was independently developed by such Major Holder without any use of the Confidential Information and by employees of such Major Holder who
have not had access to the Confidential Information, as demonstrated by files created at the time of such independent development; 
 (e)
becomes known to such Major Holder, without restriction, from a source other than the Company without breach of this Section 3.3 by such Major Holder and otherwise not in violation of the Company’s rights; 

(f) is disclosed generally to third parties by the Company without restrictions similar to those contained in this Section 3.3; or

 (g) is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however,
that such Major Holder shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order or otherwise prevent or restrict such disclosure. 

3.4 Nondisclosure and Intellectual Property Assignment Agreements. The Company agrees to require each employee of the Company to
execute a Nondisclosure and Intellectual Property Assignment Agreement and each consultant and advisor of the Company to execute an 

  
 18 

 
agreement that provides for confidential treatment of the Company’s proprietary information and assignment of intellectual property rights, in a form approved by the Board, as a condition of
employment or continued employment or engagement, as the case maybe, unless otherwise approved by the Board, including approval by the Preferred Directors. 

3.5 Stock and Option Vesting. Unless otherwise approved by the Board, including approval by the Preferred Directors, the Company agrees
that all Common Stock issued to employees, consultants, advisors, directors and officers in the future shall be subject to a repurchase option which provides that upon termination of the employment of such individual, with or without cause, the
Company shall have the option to repurchase at cost any unvested shares held by the individual, which repurchase option shall lapse twenty-five percent (25%) at the first anniversary date of the issuance of such shares and the remainder on an
equal monthly basis over the following three (3) year period following such first anniversary. In addition, unless otherwise approved by the Board, the Company agrees that each option to purchase Common Stock issued to employees, consultants,
advisors, directors and officers in the future shall vest in accordance with the following schedule: twenty-five percent (25%) of the total number of shares subject to such option shall vest at the first anniversary date of the grant thereof
and the remainder on an equal monthly basis over the following three (3) year period following such first anniversary. 
 3.6
Qualified Small Business. The Company covenants that so long as any of the shares of Preferred Stock, or the Common Stock into which such shares are converted, are held by a Holder in whose hands such shares of Common Stock are eligible to
qualify as “qualified small business stock” as defined in Section 1202(c) of the of the Internal Revenue Code of 1986, as amended (the “Code”) as of the date hereof (“Qualified Small Business Stock”),
the Company will (i) comply with any applicable filing or reporting requirements imposed by the Code on issuers of Qualified Small Business Stock, (ii) execute and deliver to the Holders, from time to time, such forms, documents, schedules
and other instruments as may be reasonably requested thereby to cause the Preferred Stock or the Common Stock into which such shares are converted, to qualify as Qualified Small Business Stock and (iii) otherwise not take any action which would
cause such shares to cease to be Qualified Small Business Stock. 
 3.7 Insurance. The Company has obtained and shall maintain from
financially sound and reputable insurers directors’ and officers’ liability insurance in an amount approved by the Board, including the Preferred Directors. 

3.8 Annual Budget. The Company shall (a) provide to the Board a copy of the proposed Annual Budget for review at least sixty
(60) days prior to the beginning of each fiscal year, and (b) the Company shall obtain the approval of the Board, including approval of the Preferred Directors, of the Annual Budget at least thirty (30) days prior to the commencement
of such fiscal year. 
 3.9 Board Matters. The Company shall reimburse the customary expenses incurred by all non-employee directors
in attending Board meetings. All non-employee directors will be compensated, if at all, uniformly for service on the Board. 

  
 19 

 3.10 Termination of Covenants. The covenants set forth in this Section 3 shall
terminate on, and be of no further force or effect at such time as the Company consummates the Initial Public Offering of the Company. 

SECTION 4 

MISCELLANEOUS 
 4.1
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors, assigns, heirs, executors and administrators and permitted
transferees of the parties hereto. 
 4.2 Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party, other than the parties hereto, and their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

4.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements
entered into and performed in the State of California solely by residents thereof without reference to principles of conflicts of laws or choice of laws. 

4.4 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 4.5 Notices. All notices, demands or other communications hereunder
shall be in writing and shall be deemed given when delivered personally, received by certified mail, return receipt requested, received by overnight courier service, or otherwise actually delivered to the parties at the addresses provided to the
Company (which the Company agrees to disclose to the other parties upon request) or such other address as a party may request by notifying the other in writing. 

4.6 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, portions of such
provisions, or such provisions in their entirety, to the extent necessary, shall be severed from this Agreement, and the balance of this Agreement shall be enforceable in accordance with its terms. 

4.7 Amendment and Waiver. Any provision of this Agreement may be amended or waived (either generally or in a particular instance and
either retroactively or prospectively) with the written consent of the Company and the Holders of at least sixty-seven percent (67%) of the Registrable Securities; provided, however, that any amendment to the rights of the Stockholders set
forth in this Agreement shall also require the written consent of the holders of at least a majority of the Common Stock held by all Stockholders. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each
Investor, Stockholder and the Company but in no event shall any amendment or waiver adversely change the obligations or rights of any party in a manner different than the other parties, except upon the written consent of

  
 20 

 
such adversely affected party. In addition, the Company may waive performance of any obligation owing to it, as to some or all of the Investors or Stockholders, or agree to accept alternatives to
such performance, without obtaining the consent of any Investors or Stockholders so long as such waiver or acceptance of alternative performance affects all Investors and Stockholders equally. 

4.8 Rights of Holders. Each Investor and Stockholder shall have the right to exercise or refrain from exercising any right or rights
that such party may have by reason of this Agreement, including, without limitation, the right to consent to the waiver or modification of any obligation under this Agreement, and such party shall not incur any liability to any other holder of any
securities of the Company as a result of exercising or refraining from exercising any such right or rights. 
 4.9 Waiver of Right of
First Refusal. Pursuant to Section 4.7 of this Agreement, the undersigned hereby waive on behalf of all Investors the rights contained in Section 2 of this Agreement with respect to the issuance of the Series E Stock pursuant to and in
accordance with the Purchase Agreement, including any notice requirements provided therein, as well as the shares of Common Stock issuable upon conversion of such Series E Stock. 

4.10 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party to this Agreement, upon any
breach or default of the other party, shall impair any such right, power or remedy of such non-breaching party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or
default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of
any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be made in writing and shall be effective only to the extent specifically set forth in such
writing. 
 4.11 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this
Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

4.12 Headings. The headings and captions used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of
which are incorporated herein by this reference. 
 4.13 Entire Agreement. This Agreement amends and restates the Prior Rights
Agreement in its entirety and constitutes the entire understanding and agreement of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings, duties or
obligations among the parties with respect to the subject matter hereof. 

  
 21 

 4.14 Further Assurances. From and after the date of this Agreement, upon the request of a
party, the other parties shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement. 

4.15 Aggregation of Stock. All shares of the Preferred Stock or Common Stock held or acquired by affiliated entities or persons shall
be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 [THE REMAINDER OF THIS PAGE
INTENTIONALLY LEFT BLANK] 

  
 22 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

									
	COMPANY:	 		 		 	ADDRESS:
				
	OBALON THERAPEUTICS, INC.	 		 		 	 5421 Avenida Encinas, Suite F
 San Diego, CA
92008

					
	By:	 	 /s/ Andy Rasdal

Andrew Rasdal,
 President
	 		 		 	

  
  
  

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

					
		 	INVESTOR:
		
		 	LUCAS VENTURE GROUP V, LP
		
		 	BY: LVG GP IV, LLC,
		 	Its Managing Member
			
		 	By:	 	 /s/ Donald Lucas

		 	Name:	 	Donald Lucas
		 	Title:	 	Managing Member
		
		 	LUCAS VENTURE GROUP XVI, LLC
		
		 	BY: LVG GP IV, LLC,
		 	Its Managing Member
			
		 	By:	 	 /s/ Donald Lucas

		 	Name:	 	Donald Lucas
		 	Title:	 	Managing Member

  
  

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTORS:
	
	BADER SULTAN BROS. CO W.L.L.
		
	By:	 	 /s/ Anwar Sultan Al Essa

	Print Name:	 	ANWAR SULTAN AL ESSA
	Title:	 	MANAGING DIRECTOR

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	AXON VENTURES VIII, LLC
	By: Axon Managers, LLC, Its Manager
		
	By:	 	 /s/ Afif Khoury

	Name:	 	 Afif Khoury

	Title:	 	 Managing Member

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

					
		 	INVESTORS:
		
		 	DOMAIN PARTNERS VII, L.P.
			
		 	By:	 	One Palmer Square Associates VII, L.L.C.
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Lisa A. Kraeutler

		 	Lisa A. Kraeutler
		 	Attorney-in-Fact
		
		 	DP VII ASSOCIATES, L.P.
			
		 	By:	 	One Palmer Square Associates VII, L.L.C.
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Lisa A. Kraeutler

		 	Lisa A. Kraeutler
		 	Attorney-in-Fact

  
  

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTORS:
	
	INTERWEST PARTNERS X, L.P.
	By:	 	InterWest Management Partners, X, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Arnold Oronsky

	Name:	 	Arnold Oronsky                                 
               ,
	Managing Director

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

					
		 	INVESTOR:
		
		 	OKAPI VENTURES, L.P.
			
		 	By:	 	Okapi Venture Partners, LLC
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Sharon Stevenson

		 	Sharon Stevenson,
		 	Managing Director
		
		 	OKAPI VENTURES II, LP
			
		 	By:	 	Okapi Venture Partners II, LLC
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Sharon Stevenson

		 	Sharon Stevenson,
		 	Managing Director

  
  

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	 INVESTOR:
  

THE ANDREA TRUST

		
	By:	 	 /s/ Lauren M. Lee

	Print Name:	 	 Lauren M. Lee

	Title:	 	 Trustee

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	THE FERAYORNI FAMILY TRUST
		
	By:	 	 /s/ Justin Ferayorni

	Print Name:	 	 Justin Ferayorni

	Title:	 	 Trustee

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	MEHTA VON MEHTA LIVING TRUST
		
	By:	 	 /s/ Anup Mehta

	Print Name:	 	 ANUP MEHTA

	Title:	 	 TRUSTEE

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	BLACK DIAMOND VENTURES 51, LLC
		
	By:	 	 /s/ Christopher B. Lucas

	Print Name:	 	 Christopher B. Lucas

	Title:	 	 Director

  
  

 

  
 [SIGNATURE PAGE TO
OBALON THERAPEUTICS, INC. 
 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT] 

 EXHIBIT A 

Lucas Venture Group V, LP 
 Lucas Venture Group XVI, LLC 

InterWest Partners X, L.P. 
 Domain Partners VII, L.P. 

DP VII Associates, L.P. 
 Okapi Ventures, L.P. 

Okapi Ventures II, L.P. 
 Amore Pacific Group 

Square 1 Bank 
 Bader Sultan & Bros. Co. W.L.L. 

Striker Asia Opportunities Fund Corporation 
 KOFC-NeoPlux
R&D-Biz Creation 2013-1 Venture Capital Fund 
 KoFC-MiraeAsset Pioneer Champ 2011-3 Venture Capital Fund 

The Andrea Trust 
 Axon Ventures VIII-2, LLC 

The Ferayorni Family Trust 
 Mehta Von Mehta Living Trust 

Black Diamond Ventures 51, LLC 

 EXHIBIT B 

STOCKHOLDERS 
 Phagia Technology,
Inc. 

 EXHIBIT C 

JOINDER AGREEMENT TO 

OBALON THERAPEUTICS FOURTH AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned hereby agrees, effective as of the date hereof, to become a party to that certain Fourth Amended and Restated Investors’
Rights Agreement (the “Agreement”) dated as of April 29, 2016, as may be amended from time to time, by and among Obalon Therapeutics, Inc. (the “Company”) and the other parties from time to time named therein,
and for all purposes of the Agreement, the undersigned shall be included within the term Stockholder, as defined in the Agreement. The address to which notices shall be sent to the undersigned are as follows: 

Address:
                                         
                                         
                                         
                                     . 

 

			
	  

	Print Name:	 	  

	Date:	 	  

  

			
	Acknowledged and Accepted:
	
	OBALON THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	  

	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]